Attendees “take aways” – Monterey 2019

Thanks to all attendees who contributed these comments during the 2019 Monterey Meeting as to “how they will change their practice”

  • Confirm MDx plus MRI for PSA elevation after meg biopsy. Earlier chemo in mCaP
  • Refer transgender candidates to a multidisciplinary program
  • Take CPT surveys better.
  • Improve evaluation for UTI/ monitor hypospadias repair results better.
  • Check testosterone levels during androgen suppressive therapy.
  • Implement more standards for patient care
  • Implement standardized routine for VOIDING TRIAL.
  • Add new robotic techniques with new robotic instruments for operations I currently perform.
  • Do more pediatric laparoscopy.
  • Get training to operate endoscopic and robotics.
  • Do two-stage hypospadias repairs rather than one stage.
  • Better documentation for billing.
  • Implement new strategic planning for enhancing patient care.
  • Change my surveillance protocol for low risk ca prostate.
  • Check on urine flow cytometry.
  • Awareness of practices surrounding robot assisted techniques in US, that may be brought to Australia for practice.
  • Utilize telemedicine.
  • Consider dual therapy for overactive bladder
  • Modify how I use intravesicle chemo
  • Modify my management of female pelvic disorders and bladder cancer
  • Apply new management guidelines for pelvic organ prolapse. New technologies in bladder cancer – blue light
  • Improved understanding of chemo with RCC, commitment to follow guidelines
  • Better understanding of treatment of my transgender patients reconstructions.
  • Change duration of BCG maintenance.
  • New awareness of issues regarding transgender patients.
  • Consider to use more simulation study to perfect surgical techniques.
  • Alter bladder cancer algorithm for chemo therapy.
  • Surveillance  of  low  risk  prostate  cancer  and  treatment options for BPS
  • Apply  new  approach  to  intravesical  guidelines  with  BCG shortage
  • Use active surveillance with Low risk prostate cancer.
  • Adding options for the management of IC
  • Modify slightly how I inject Botox
  • Management of complex cancer cases
  • Improved active surveillance criteria for men with CAP
  • Use  all  appropriate  Subspecialities  in  the  process  of transitioning adolescent SB patients to adult services.
  • Utilize the pearls of wisdom set forth by Dr. Elliot regarding surgical management of female urethral strictures.
  • Better assess elderly patients for surgery
  • More proactive in treating stone disease and fertility in patients
  • Increase testosterone monitoring in prostate cancer patients.
  • Refer recurrent strictures out.
  • Modify  my  management  of  pelvic  disorders,  pediatric problems, sexual disorders, GU tumors, and prostate cancer
  • Increased preparation for the ability to manage advanced prostate cancer
  • Check T with PSA on ADT
  • I  perform  volunteer  teaching  missions  overseas.  The updated knowledge I received today will improve my educational efforts.
  • Sounder practice
  • Pelvic floor medicine care
  • More testosterone monitoring in prostate cancer patients.
  • More Pre-op management of geriatric patients
  • Robotic prostatectomy is favored. Use Urethroplasy earlier in algorithm.
  • Continue to testosterone levels in conjunction with PSA levels when on ADT.
  • Use of gemcitabine instead of mitomycin.
  • Use larger ureteral access sheath.
  • Change in frequency of urodynamics.
  • I am going to start performing xiaflex and Botox procedures.
  • Use alternatives to BCG when appropriate.
  • Consider biopsy/resection of the prostate urethra more often during TURBT.
  • Use ureteral access sheath more
  • Consider adding Xiaflex and/or botox to the practice.
  • Try  to  use  ultra  follow  dose  ct,  maybe  not  stick  in  as  many stents.
  • Do further investigation to the cause of the Twinkle artifact in US.
  • BCG alternative considerations.
  • Alpha blockers before ureteral access sheath insertion.
  • Better able to discuss other intravesical options for NMIBC.
  • Increase use of blue light cystoscopy.
  • Better options for NMIBC with BCG shortage.
  • New treatment strategies.
  • Use of MRI in prostate cancer
  • Change surveillance recommendations in low risk seminomas. Alternative intravesicle chemo in BCG shortage era.
  • Increase use of disposable scopes, change informed consent for slings, document patient focused outcomes
  • Induction chemo when indicated. Increased Flomax prior to Sheath.
  • Tamsulosin before URS?
  • Will be receiving training on cystoscopy
  • Use BCG in specific indications
  • Increase use of ureteroscopy for stone management
  • Continue to evaluate the intravesical therapies available in an era of BCG shortage, utilizing AUA guidelines, white papers and societal recommendations.
  • More commitment to genetic testing
  • Utilize more advanced radiologic studies
  • Explore latest imaging options available for cap patient
  • Consider advanced imaging earlier
  • Have pathologist report on cribiform pattern on grade 7 prostate cancers.
  • Ask pathologists to report cribiform pattern in Gleason 4 Lobby for PET imaging in prostate ca Recommend RestoreX post prostatectomy
  • Restorex for penile length